SUBSCRIBERS

Roche drug cocktail doubles chance of holding lung cancer at bay

Published Thu, Dec 7, 2017 · 09:50 PM

Zurich

ADDING Roche's immunotherapy Tecentriq to older drugs doubled the percentage of lung cancer patients who survived a year without their disease advancing, an outcome that some experts labelled as unprecedented.

Thirty…

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece
P&G raises annual core profit forecast on resilient demand, price hikes
Cordlife calls for trading halt after shares sink to all-time low, pending announcement
Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom
Swiss watch exports plunge as China and Hong Kong demand dries up
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

Companies & Markets

Roche drug cocktail doubles chance of holding lung cancer at bay

Consumer & Healthcare

Gazelle Ventures makes cash offer for No Signboard shares at S$0.0021 apiece

P&G raises annual core profit forecast on resilient demand, price hikes

Cordlife calls for trading halt after shares sink to all-time low, pending announcement

Marina Bay Sands Q1 profit surges 51.5% to US$597 million on tourism boom

Swiss watch exports plunge as China and Hong Kong demand dries up

Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

SECTIONS

LIFESTYLE

Follow BT